Objective:
Biochemical observations of the decrease in mortality rate and prediction of the degree of coronary artery stenosis before symptomatic improvement are gaining importance. In our study, we aimed to evaluate the etiological value of the recently discovered resistin biomolecule in coronary atherosclerosis pathogenesis.
Methods:
In this study, we evaluated and compared serum resistin levels in patients with angiographically proven coronary artery disease (stenosis ratio >25%) (n=43) and in the control group with angiographically proven normal coronary artery diameter (stenosis ratio <25%) (n=25). Furthermore, serum glucose, insulin, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), homocysteine, and high-sensitivity C-reactive protein (hsCRP) levels and homeostatic model assessment- insulin resistance (HOMA-IR) were evaluated to compare resistin with other etiological factors.
Results:
Resistin levels were higher in the patient group (2.32±1.1) than the control group (2.25±0.7), but no significant difference was found between the groups (p=0.773). Resistin levels were significantly lower in antihyperlipidemic agent users in both patient and control groups (p < 0.05). Other group characteristics did not show significant differences in resistin levels (p>0.05). While considering both patient and control group correlations, we determined a positive correlation between resistin and fasting insulin (p=0.012, r=0.304), HOMA-IR (p=0.046, r=0.243), homocysteine (p=0.05; r 0.239), and hsCRP (p=0.029, r=0.265).
Conclusion:
Resistin values differ between patients and control subjects but were not statistically significant. The modifying effect of anti-hyperlipidemic agents over serum resistin levels may have a preventive role in the process of atherosclerosis. We think that effective results will be obtained in raising the selected threshold level of atherosclerosis diagnosis and increasing the number of patients.
Keywords: Resistin, coronary artery disease, hsCRP, inflammation